| In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs Z Gagic, D Ruzic, N Djokovic, T Djikic, K Nikolic Frontiers in chemistry 7, 873, 2020 | 88 | 2020 |
| Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies K Nikolic, L Mavridis, T Djikic, J Vucicevic, D Agbaba, K Yelekci, ... Frontiers in neuroscience 10, 198455, 2016 | 81 | 2016 |
| Synthesis and screening of human monoamine oxidase‐A inhibitor effect of new 2‐pyrazoline and hydrazone derivatives B Evranos‐Aksöz, İ Baysal, S Yabanoğlu‐Çiftçi, T Djikic, K Yelekçi, ... Archiv der Pharmazie 348 (10), 743-756, 2015 | 33 | 2015 |
| Synthesis, molecular docking and anticancer activity of diflunisal derivatives as cyclooxygenase enzyme inhibitors GP Coşkun, T Djikic, TB Hayal, N Türkel, K Yelekçi, F Şahin, ... Molecules 23 (8), 1969, 2018 | 28 | 2018 |
| Application of in vitro PAMPA technique and in silico computational methods for blood-brain barrier permeability prediction of novel CNS drug candidates M Radan, T Djikic, D Obradovic, K Nikolic European Journal of Pharmaceutical Sciences 168, 106056, 2022 | 25 | 2022 |
| Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease S Abás, S Rodriguez-Arevalo, A Bagan, C Grinan-Ferre, F Vasilopoulou, ... Journal of medicinal chemistry 63 (7), 3610-3633, 2020 | 25 | 2020 |
| Synthesis, anticancer activity, and molecular modeling of etodolac‐thioether derivatives as potent methionine aminopeptidase (type II) inhibitors I Çoruh, Ö Çevik, K Yelekçi, T Djikic, ŞG Küçükgüzel Archiv der Pharmazie 351 (3-4), 1700195, 2018 | 21 | 2018 |
| Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease S Rodriguez-Arevalo, A Bagan, C Grinan-Ferre, F Vasilopoulou, M Pallas, ... European journal of medicinal chemistry 222, 113540, 2021 | 18 | 2021 |
| In silico identification of novel 5-HT2A antagonists supported with ligand- and target-based drug design methodologies M Radan, D Ruzic, M Antonijevic, T Djikic, K Nikolic Journal of Biomolecular Structure and Dynamics 39 (5), 1819-1837, 2021 | 15 | 2021 |
| Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities T Djikic, Y Martí, F Spyrakis, T Lau, P Benedetti, G Davey, P Schloss, ... Journal of Biomolecular Structure and Dynamics 37 (2), 291-306, 2019 | 12 | 2019 |
| The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches D Obradović, M Radan, T Đikić, MP Nikolić, S Oljačić, K Nikolić Journal of Pharmaceutical and Biomedical Analysis 211, 114593, 2022 | 8 | 2022 |
| An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease N Djokovic, D Ruzic, T Djikic, S Cvijic, J Ignjatovic, S Ibric, K Baralic, ... Molecular Informatics 40 (5), 2000187, 2021 | 8 | 2021 |
| Synthesis, Molecular Modelling and antibacterial activity against Helicobacter pylori of novel diflunisal derivatives as urease enzyme inhibitors GP Coşkun, T Djikic, S Kalaycı, K Yelekçi, F Şahin, ŞG Küçükgüzel Letters in Drug Design & Discovery 16 (4), 392-400, 2019 | 7 | 2019 |
| Drug design for CNS diseases: Polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies. Front. Neurosci. 2016; 10: 265 K Nikolic, L Mavridis, T Djikic, J Vucicevic, D Agbaba, K Yelekci, ... | 5 | |
| Design and Discovery of Kinase Inhibitors Using Docking Studies T Djikic, Z Gagic, K Nikolic Molecular Docking for Computer-Aided Drug Design, 337-365, 2021 | 1 | 2021 |
| Deciphering Imidazoline Off‐targets by Fishing in the Class A of GPCR field T Djikic, J Vucicevic, J Laurila, M Radi, N Veljkovic, H Xhaard, K Nikolic Molecular informatics 39 (7), 1900165, 2020 | 1 | 2020 |
| 3D-Quantitative Structure-Activity Relationship and design of novel Rho-associated protein kinases-1 (ROCK1) inhibitors M Beljkaš, J Rebić, M Radan, T Đikić, S Oljačić, K Nikolić 2nd International Conference on Chemo and Bioinformatics, BOOK OF …, 2023 | | 2023 |
| Virtual Docking, design and in silico ADMET profiling of novel Rho-associated protein kinases-1 (ROCK1) inhibitors M Beljkaš, J Rebić, M Radan, T Đikić, S Oljačić, K Nikolić 2nd International Conference on Chemo and Bioinformatics ICCBIKG 2023, BOOK …, 2023 | | 2023 |
| Polypharmacological strategy in rational drug design of new dual 5HT2A/D2-R antagonists as potentially effective therapeutics of complex neurological and mental disorders K Nikolić, M Radan, T Đikić 8th and final ERNEST Meeting" GPCR structure and function: The present and …, 2023 | | 2023 |
| Discovery of new chemotypes of dual 5-HT2A/D2 receptor antagonists with a strategy of drug design methodologies M Radan, T Djikic, K Nikolic Future Medicinal Chemistry 14 (13), 963-989, 2022 | | 2022 |
Katarina NikolicProfessor of Pharmaceutical chemistry, University of BelgradeVerified email at pharmacy.bg.ac.rs
